Professor Michael Barry:

Apologies. Members can see the timelines on the list from EMA marketing authorisation to when the drug reimbursement recommendation is made. The drug is reimbursed about a month after that. We will have that information at the end of the year. We account for 222 days. I wish it was less; we are working hard to make sure it is less. We are not responsible for the vast majority of the delays. Table 3 shows the number of orphan drugs reimbursed over the past five years.

I apologise for going over time.